Thomas Gad | Founder, Interim CEO and President |
Bo Kruse | CFO |
Sue Smith | Chief Commercial Officer |
Vignesh Rajah | Chief Medical Officer |
Alec Stranahan | Bank of America |
Robert Burns | HC Wainwright |
Charles Zhu | Guggenheim |
Joseph Thome | Cowen & Company |
Tessa Romero | JP Morgan |
Mike Ulz | Morgan Stanley |
William Maughan | Canaccord Genuity |
Good morning and welcome to the Y-mAbs Therapeutics, Inc., Earnings Conference Call for the Second Quarter 2022. Today's conference is being recorded.
Let me quickly remind you that the following discussion contains certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's quarterly report on Form 10-K for the fiscal second quarter ended June 30, 2022, as filed with the SEC on August 8, 2022. At this time, I would like to turn the conference over to Thomas Gad, the Company's Founder, Interim CEO and President.